Print

Mesoblast Limited Market Exclusivity For Its Biologic Products Strengthened By New United States Health Care Act  
4/6/2010 10:41:06 AM

Melbourne, April 6, 2010 (ABN Newswire) - Australian regenerative medicine company and biologic innovator, Mesoblast Limited (ASX:MSB) (OTC:MBLTY), today provided an assessment on how the recently enacted United States Patient Protection and Affordable Care Act (HB 3590) is expected to have a positive impact on the commercial prospects for both Mesoblast and its United States-associated company, Angioblast Systems Inc.